In this issue:
Retzius-sparing vs conventional RARP
Prostate cancer risks in male BRCA1 and BRCA2 mutation carriers
Dementia and depression after ADT
Whole-pelvis radiation for Gleason 5 prostate cancer
High-dose ultrahypofractionated radiation therapy
STAMPEDE trial long-term survival
Pembrolizumab for treatment-refractory mCRPC
Sequencing of ADT with external-beam radiotherapy
Bone lesions and outcomes in mCRPC treated with enzalutamide
Antibody targeting STEAP1 in mCRPC
Please login below to download this issue (PDF)